RAPP
Rapport Therapeutics, Inc.
Next earnings Aug 5, 2026 · consensus $-0.99 EPS
Last earnings +7.7% on 2026-05-07
$40.06
▲ +2.96%$40.06▲ +268.20%
over 1Y
L $10.88EODHDH $40.06
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.0%
1W+4.9%
1M+1.4%
3M+43.9%
YTD+42.5%
1Y+268.2%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 17 analysts
Buy
Conservative balance sheet (liabilities/equity 0.06x).
Return on equity -23.0% · latest
Rapport Therapeutics, Inc. shows limited reported revenue, and -23.0% ROE.
Financials · annual, by fiscal year
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$36.2M | -$83.1M | -$125M |
| Net income | -$34.8M | -$78.3M | -$111M |
| Diluted EPS | -$23.10 | -$3.78 | -$2.86 |
| Net margin | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$1.86B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-5.8%
FCF yield-4.6%
Quality & risk
ROIC (est.)-20.4%
Free cash flow-$88.1M
Total debt—
Net cash$52.6M
Piotroski F-Score2/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+31.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗4Period ending 2026-06-102026-06-10open ↗4Period ending 2026-06-102026-06-10open ↗4Period ending 2026-06-102026-06-10open ↗4Period ending 2026-06-102026-06-10open ↗4Period ending 2026-06-102026-06-10open ↗4Period ending 2026-06-102026-06-10open ↗4Period ending 2026-06-102026-06-10open ↗4Period ending 2026-06-102026-06-10open ↗8-KPeriod ending 2026-06-102026-06-10open ↗4Period ending 2026-05-262026-05-28open ↗144Filing2026-05-27open ↗SCHEDULE 13G/AFiling2026-05-15open ↗
Frequently asked
- Is Rapport Therapeutics, Inc. (RAPP) a buy?
- RAPP currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.06x).
- What is Rapport Therapeutics, Inc.'s quality score?
- RAPP scores 36.179487179487175/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0002012593, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 1:20:32 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.